When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RUBY - Rubius Therapeutics updates on clinical progress of RTX-240 trial
Rubius Therapeutics Inc.
Rubius Therapeutics (NASDAQ:RUBY) has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240, an allogeneic cellular therapy for the treatment of patients with relapsed/refractory or locally advanced solid tumors.
More news on: Rubius Therapeutics, Inc., Healthcare stocks news,